answer text |
<p>NHS England has advised that representatives from NHS England, the Department of
Health, the National Institute for Health and Care Excellence, ten key cancer charities,
and the pharmaceutical industry met on 4 December 2014, to discuss the future of cancer
drugs commissioning. They have committed to establishing a working group, to meet
early in the new year, to develop a robust process to support the sustainable long-term
commissioning of cancer drugs.</p><p> </p><p> </p><p> </p><p>The external review of
the pathways for the development, assessment, and adoption of innovative medicines
and medical technology will consider how to speed up access for National Health Service
patients to cost-effective new diagnostics, medicines and devices. We are still establishing
the processes by which the review will link with other pieces of work in progress
and we expect the review will be able to take account of the work NHS England is coordinating
on the commissioning of cancer drugs.</p><p> </p>
|
|